{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVA+Gallbladder+Cancer+AJCC+v7", "query": { "condition": "Stage IVA Gallbladder Cancer AJCC v7" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:49:10.104Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03278106", "title": "TAS-102 in Treating Advanced Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Stage III Gallbladder Cancer AJCC v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-20", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03278106" }, { "nct_id": "NCT03768414", "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Gallbladder Cancer AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Distal Bile Duct Cancer AJCC v8", "Stage IIIA Gallbladder Cancer AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Distal Bile Duct Cancer AJCC v8", "Stage IIIB Gallbladder Cancer AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Gallbladder Cancer AJCC v8", "Stage IVB Gallbladder Cancer AJCC v8", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2019-02-07", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 692, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03768414" }, { "nct_id": "NCT04072445", "title": "Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Bile Duct Carcinoma", "Advanced Gallbladder Carcinoma", "Refractory Bile Duct Carcinoma", "Refractory Gallbladder Carcinoma", "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Gallbladder Cancer AJCC v8", "Stage III Intrahepatic Bile Duct Cancer AJCC v8", "Stage IIIA Distal Bile Duct Cancer AJCC v8", "Stage IIIA Gallbladder Cancer AJCC v8", "Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8", "Stage IIIB Distal Bile Duct Cancer AJCC v8", "Stage IIIB Gallbladder Cancer AJCC v8", "Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Bile Duct Cancer AJCC v8", "Stage IVA Gallbladder Cancer AJCC v8", "Stage IVB Gallbladder Cancer AJCC v8" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-10-18", "completion_date": "2021-08-13", "has_results": true, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072445" }, { "nct_id": "NCT01825603", "title": "ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ampulla of Vater Adenocarcinoma", "Gallbladder Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage III Ampulla of Vater Cancer", "Stage III Intrahepatic Cholangiocarcinoma", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Hilar Cholangiocarcinoma", "Stage IIIB Gallbladder Cancer", "Stage IIIB Hilar Cholangiocarcinoma", "Stage IV Ampulla of Vater Cancer", "Stage IVA Gallbladder Cancer", "Stage IVA Hilar Cholangiocarcinoma", "Stage IVA Intrahepatic Cholangiocarcinoma", "Stage IVA Pancreatic Cancer", "Stage IVB Gallbladder Cancer", "Stage IVB Hilar Cholangiocarcinoma", "Stage IVB Intrahepatic Cholangiocarcinoma", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "ADH-1", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 17, "start_date": "2013-04-09", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2023-12-28", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01825603" }, { "nct_id": "NCT03257761", "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extrahepatic Bile Duct Adenocarcinoma, Biliary Type", "Gallbladder Adenocarcinoma, Biliary Type", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Cholangiocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Gallbladder Cancer AJCC V7", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage III Intrahepatic Cholangiocarcinoma AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7", "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7", "Unresectable Gallbladder Carcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-02-07", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 3, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257761" }, { "nct_id": "NCT01643499", "title": "Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of Unknown Primary", "Adult Primary Cholangiocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Duct Cell Adenocarcinoma of the Pancreas", "Intestinal Adenocarcinoma of the Stomach", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Carcinoma of Unknown Primary", "Metastatic Extrahepatic Bile Duct Cancer", "Mixed Adenocarcinoma of the Stomach", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Newly Diagnosed Carcinoma of Unknown Primary", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage III Pancreatic Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Rectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colon Cancer", "Stage IVA Gallbladder Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Gallbladder Cancer", "Stage IVB Rectal Cancer", "Unresectable Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2012-03-26", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 2, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643499" }, { "nct_id": "NCT02042443", "title": "Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Cholangiocarcinoma", "Advanced Adult Hepatocellular Carcinoma", "BCLC Stage C Adult Hepatocellular Carcinoma", "BCLC Stage D Adult Hepatocellular Carcinoma", "Hilar Cholangiocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Recurrent Adult Liver Carcinoma", "Recurrent Childhood Liver Cancer", "Recurrent Extrahepatic Bile Duct Carcinoma", "Recurrent Gallbladder Carcinoma", "Stage II Gallbladder Cancer", "Stage III Childhood Hepatocellular Carcinoma", "Stage IIIA Gallbladder Cancer", "Stage IIIB Gallbladder Cancer", "Stage IV Childhood Hepatocellular Carcinoma", "Stage IV Distal Bile Duct Cancer", "Stage IVA Gallbladder Cancer", "Stage IVB Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 53, "start_date": "2014-02", "completion_date": "2017-04-30", "has_results": true, "last_update_posted_date": "2017-09-12", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 295, "location_summary": "Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02042443" }, { "nct_id": "NCT00075504", "title": "Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Gallbladder Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIB Gallbladder Cancer", "Stage IVA Gallbladder Cancer", "Stage IVB Gallbladder Cancer" ], "interventions": [ { "name": "triapine", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-11", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075504" }, { "nct_id": "NCT02392637", "title": "Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7", "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2015-04-02", "completion_date": "2020-08-13", "has_results": true, "last_update_posted_date": "2022-02-02", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392637" }, { "nct_id": "NCT02520141", "title": "Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Stage III Gallbladder Cancer AJCC v7", "Stage III Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7", "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7", "Unresectable Gallbladder Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-12-29", "completion_date": "2022-06-29", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-05-22T07:49:10.104Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02520141" } ] }